Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Chinese Patent Medicine Market by Disease Type (Cardiovascular and Cerebrovascular Diseases, Tumor Diseases, Respiratory System Diseases, Musculoskeletal Diseases, Digestive System Diseases, Others), by Dosage Type (Injection, Capsule, Pills, Syrups, Others) and by End User (Hospitals, Pharmacies or Drugstores, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

A03185

Pages: NA

Charts: NA

Tables: NA

Chinese patent medicines refer to herbal medicines, mainly extracted condensed pills called teapills, which are usually small, spherical, and black. Patents may come for various types of medicines such as syrups, dripping pills, liquids, capsules, powders, granules, and instant teas, which are manufactured by Chinese companies and exported within and outside China.

The major factors that contribute to the growth of the Chinese patent medicines market include the increasing prevalence of cardiovascular & cerebrovascular diseases, rise in health concerns among people, rising popularity of Chinese patent medicine with less toxicity & fewer side effects, and high demand for traditional Chinese medicine among patients. However, heavy metal contamination and stringent government regulations for prohibited ingredients may restrain the market. The development of drugs with less metal contamination and increasing ageing population presents a major opportunity for the market growth.

The Chinese patent medicines market is segmented on the basis of disease type, dosage forms, end user, and region. Based on disease type, the market is divided into cardiovascular & cerebrovascular diseases, tumor diseases, respiratory system diseases, musculoskeletal diseases, digestive system diseases, and others. On the basis of dosage form the market is segmented into injection, capsule, pills, syrups, and others. According to end user, the market is divided into hospitals, pharmacies or drugstores, and others.

The key players that operate in this market include Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, Yangtze River Pharmaceutical (Group) Co., Ltd., China Resources Pharmaceutical Group Limited, Shanghai Pharmaceutical Co., Ltd., Taiji Group Co., Ltd., Tasly.Phar. International Co., Ltd., Yunnan Baiyao Group Co., Ltd., Zhangzhou Pientzehuang Pharmaceutical Co., Ltd., Shandong Dong-E E-Jiao Co., Ltd., and Tibet Rhodiola Pharmaceutical Holding Co., Ltd.

Key Benefits

  • The study provides an in-depth analysis of the Chinese patent medicines market with current trends and future estimations to elucidate imminent investment pockets.
  • The report provides information about the current and upcoming trends in the Chinese patent medicines market from 2016 to 2023, which helps determine prevailing opportunities.
  • Comprehensive analysis of factors that drive and restrict the growth of the Chinese patent medicines market has been provided.
  • Identification of factors that are instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a regional scale have been provided.
  • Key market players within the market have been profiled in this report and their strategies thoroughly analyzed, which help understand the competitive outlook of the Chinese patent medicines market.

Chinese Patent Medicine Market Key Segments:

By Disease Type

  • Cardiovascular and Cerebrovascular Diseases
  • Tumor Diseases
  • Respiratory System Diseases
  • Musculoskeletal Diseases
  • Digestive System Diseases
  • Others

By Dosage Type

  • Injection
  • Capsule
  • Pills
  • Syrups
  • Others

By End User

  • Hospitals
  • Pharmacies or Drugstores
  • Others

 Key Market Segments

  • By Disease Type
    • Cardiovascular and Cerebrovascular Diseases
    • Tumor Diseases
    • Respiratory System Diseases
    • Musculoskeletal Diseases
    • Digestive System Diseases
    • Others
  • By Dosage Type
    • Injection
    • Capsule
    • Pills
    • Syrups
    • Others
  • By End User
    • Hospitals
    • Pharmacies or Drugstores
    • Others
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Tasly.Phar. International Co., Ltd.
  • China Resources Pharmaceutical Group Limited
  • Taiji Group Co., Ltd.
  • Yangtze River Pharmaceutical (Group) Co., Ltd.
  • Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.
  • Shanghai Pharmaceutical Co., Ltd.
  • Yunnan Baiyao Group Co., Ltd.
  • Tibet Rhodiola Pharmaceutical Holding Co., Ltd.
  • Shandong Dong-E E-Jiao Co., Ltd.
  • Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: CHINESE PATENT MEDICINE MARKET, BY DISEASE TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Disease Type

    • 4.2. Cardiovascular And Cerebrovascular Diseases

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Tumor Diseases

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Respiratory System Diseases

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Musculoskeletal Diseases

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Digestive System Diseases

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

    • 4.7. Others

      • 4.7.1. Key Market Trends, Growth Factors and Opportunities

      • 4.7.2. Market Size and Forecast, By Region

      • 4.7.3. Market Share Analysis, By Country

  • CHAPTER 5: CHINESE PATENT MEDICINE MARKET, BY DOSAGE TYPE

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Dosage Type

    • 5.2. Injection

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Capsule

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Pills

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Syrups

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Others

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

  • CHAPTER 6: CHINESE PATENT MEDICINE MARKET, BY END USER

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By End User

    • 6.2. Hospitals

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Pharmacies Or Drugstores

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Others

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

  • CHAPTER 7: CHINESE PATENT MEDICINE MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Disease Type

      • 7.2.3. Market Size and Forecast, By Dosage Type

      • 7.2.4. Market Size and Forecast, By End User

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S.

        • 7.2.6.1 Market size and forecast, disease type

        • 7.2.6.2 Market size and forecast, dosage type

        • 7.2.6.3 Market size and forecast, end user

      • 7.2.7. Canada

        • 7.2.7.1 Market size and forecast, disease type

        • 7.2.7.2 Market size and forecast, dosage type

        • 7.2.7.3 Market size and forecast, end user

      • 7.2.8. Mexico

        • 7.2.8.1 Market size and forecast, disease type

        • 7.2.8.2 Market size and forecast, dosage type

        • 7.2.8.3 Market size and forecast, end user

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Disease Type

      • 7.3.3. Market Size and Forecast, By Dosage Type

      • 7.3.4. Market Size and Forecast, By End User

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France

        • 7.3.6.1 Market size and forecast, disease type

        • 7.3.6.2 Market size and forecast, dosage type

        • 7.3.6.3 Market size and forecast, end user

      • 7.3.7. Germany

        • 7.3.7.1 Market size and forecast, disease type

        • 7.3.7.2 Market size and forecast, dosage type

        • 7.3.7.3 Market size and forecast, end user

      • 7.3.8. Italy

        • 7.3.8.1 Market size and forecast, disease type

        • 7.3.8.2 Market size and forecast, dosage type

        • 7.3.8.3 Market size and forecast, end user

      • 7.3.9. Spain

        • 7.3.9.1 Market size and forecast, disease type

        • 7.3.9.2 Market size and forecast, dosage type

        • 7.3.9.3 Market size and forecast, end user

      • 7.3.10. UK

        • 7.3.10.1 Market size and forecast, disease type

        • 7.3.10.2 Market size and forecast, dosage type

        • 7.3.10.3 Market size and forecast, end user

      • 7.3.11. Russia

        • 7.3.11.1 Market size and forecast, disease type

        • 7.3.11.2 Market size and forecast, dosage type

        • 7.3.11.3 Market size and forecast, end user

      • 7.3.12. Rest Of Europe

        • 7.3.12.1 Market size and forecast, disease type

        • 7.3.12.2 Market size and forecast, dosage type

        • 7.3.12.3 Market size and forecast, end user

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Disease Type

      • 7.4.3. Market Size and Forecast, By Dosage Type

      • 7.4.4. Market Size and Forecast, By End User

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China

        • 7.4.6.1 Market size and forecast, disease type

        • 7.4.6.2 Market size and forecast, dosage type

        • 7.4.6.3 Market size and forecast, end user

      • 7.4.7. Japan

        • 7.4.7.1 Market size and forecast, disease type

        • 7.4.7.2 Market size and forecast, dosage type

        • 7.4.7.3 Market size and forecast, end user

      • 7.4.8. India

        • 7.4.8.1 Market size and forecast, disease type

        • 7.4.8.2 Market size and forecast, dosage type

        • 7.4.8.3 Market size and forecast, end user

      • 7.4.9. South Korea

        • 7.4.9.1 Market size and forecast, disease type

        • 7.4.9.2 Market size and forecast, dosage type

        • 7.4.9.3 Market size and forecast, end user

      • 7.4.10. Australia

        • 7.4.10.1 Market size and forecast, disease type

        • 7.4.10.2 Market size and forecast, dosage type

        • 7.4.10.3 Market size and forecast, end user

      • 7.4.11. Thailand

        • 7.4.11.1 Market size and forecast, disease type

        • 7.4.11.2 Market size and forecast, dosage type

        • 7.4.11.3 Market size and forecast, end user

      • 7.4.12. Malaysia

        • 7.4.12.1 Market size and forecast, disease type

        • 7.4.12.2 Market size and forecast, dosage type

        • 7.4.12.3 Market size and forecast, end user

      • 7.4.13. Indonesia

        • 7.4.13.1 Market size and forecast, disease type

        • 7.4.13.2 Market size and forecast, dosage type

        • 7.4.13.3 Market size and forecast, end user

      • 7.4.14. Rest of Asia Pacific

        • 7.4.14.1 Market size and forecast, disease type

        • 7.4.14.2 Market size and forecast, dosage type

        • 7.4.14.3 Market size and forecast, end user

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Disease Type

      • 7.5.3. Market Size and Forecast, By Dosage Type

      • 7.5.4. Market Size and Forecast, By End User

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil

        • 7.5.6.1 Market size and forecast, disease type

        • 7.5.6.2 Market size and forecast, dosage type

        • 7.5.6.3 Market size and forecast, end user

      • 7.5.7. South Africa

        • 7.5.7.1 Market size and forecast, disease type

        • 7.5.7.2 Market size and forecast, dosage type

        • 7.5.7.3 Market size and forecast, end user

      • 7.5.8. Saudi Arabia

        • 7.5.8.1 Market size and forecast, disease type

        • 7.5.8.2 Market size and forecast, dosage type

        • 7.5.8.3 Market size and forecast, end user

      • 7.5.9. UAE

        • 7.5.9.1 Market size and forecast, disease type

        • 7.5.9.2 Market size and forecast, dosage type

        • 7.5.9.3 Market size and forecast, end user

      • 7.5.10. Argentina

        • 7.5.10.1 Market size and forecast, disease type

        • 7.5.10.2 Market size and forecast, dosage type

        • 7.5.10.3 Market size and forecast, end user

      • 7.5.11. Rest of LAMEA

        • 7.5.11.1 Market size and forecast, disease type

        • 7.5.11.2 Market size and forecast, dosage type

        • 7.5.11.3 Market size and forecast, end user

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning,2022

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Yangtze River Pharmaceutical (Group) Co., Ltd.

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. China Resources Pharmaceutical Group Limited

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. Shanghai Pharmaceutical Co., Ltd.

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Taiji Group Co., Ltd.

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Tasly.Phar. International Co., Ltd.

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Yunnan Baiyao Group Co., Ltd.

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Shandong Dong-E E-Jiao Co., Ltd.

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. Tibet Rhodiola Pharmaceutical Holding Co., Ltd.

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL CHINESE PATENT MEDICINE MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 2. CHINESE PATENT MEDICINE MARKET FOR CARDIOVASCULAR AND CEREBROVASCULAR DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. CHINESE PATENT MEDICINE MARKET FOR TUMOR DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. CHINESE PATENT MEDICINE MARKET FOR RESPIRATORY SYSTEM DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. CHINESE PATENT MEDICINE MARKET FOR MUSCULOSKELETAL DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. CHINESE PATENT MEDICINE MARKET FOR DIGESTIVE SYSTEM DISEASES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. CHINESE PATENT MEDICINE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL CHINESE PATENT MEDICINE MARKET, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 9. CHINESE PATENT MEDICINE MARKET FOR INJECTION, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. CHINESE PATENT MEDICINE MARKET FOR CAPSULE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. CHINESE PATENT MEDICINE MARKET FOR PILLS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. CHINESE PATENT MEDICINE MARKET FOR SYRUPS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. CHINESE PATENT MEDICINE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. GLOBAL CHINESE PATENT MEDICINE MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 15. CHINESE PATENT MEDICINE MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. CHINESE PATENT MEDICINE MARKET FOR PHARMACIES OR DRUGSTORES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. CHINESE PATENT MEDICINE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. CHINESE PATENT MEDICINE MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. NORTH AMERICA CHINESE PATENT MEDICINE, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 20. NORTH AMERICA CHINESE PATENT MEDICINE, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 21. NORTH AMERICA CHINESE PATENT MEDICINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 22. NORTH AMERICA CHINESE PATENT MEDICINE, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 23. U.S. CHINESE PATENT MEDICINE, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 24. U.S. CHINESE PATENT MEDICINE, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 25. U.S. CHINESE PATENT MEDICINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 26. CANADA CHINESE PATENT MEDICINE, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 27. CANADA CHINESE PATENT MEDICINE, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 28. CANADA CHINESE PATENT MEDICINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 29. MEXICO CHINESE PATENT MEDICINE, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 30. MEXICO CHINESE PATENT MEDICINE, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 31. MEXICO CHINESE PATENT MEDICINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 32. EUROPE CHINESE PATENT MEDICINE, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 33. EUROPE CHINESE PATENT MEDICINE, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 34. EUROPE CHINESE PATENT MEDICINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 35. EUROPE CHINESE PATENT MEDICINE, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 36. FRANCE CHINESE PATENT MEDICINE, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 37. FRANCE CHINESE PATENT MEDICINE, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 38. FRANCE CHINESE PATENT MEDICINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 39. GERMANY CHINESE PATENT MEDICINE, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 40. GERMANY CHINESE PATENT MEDICINE, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 41. GERMANY CHINESE PATENT MEDICINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 42. ITALY CHINESE PATENT MEDICINE, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 43. ITALY CHINESE PATENT MEDICINE, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 44. ITALY CHINESE PATENT MEDICINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 45. SPAIN CHINESE PATENT MEDICINE, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 46. SPAIN CHINESE PATENT MEDICINE, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 47. SPAIN CHINESE PATENT MEDICINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 48. UK CHINESE PATENT MEDICINE, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 49. UK CHINESE PATENT MEDICINE, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 50. UK CHINESE PATENT MEDICINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 51. RUSSIA CHINESE PATENT MEDICINE, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 52. RUSSIA CHINESE PATENT MEDICINE, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 53. RUSSIA CHINESE PATENT MEDICINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 54. REST OF EUROPE CHINESE PATENT MEDICINE, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 55. REST OF EUROPE CHINESE PATENT MEDICINE, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 56. REST OF EUROPE CHINESE PATENT MEDICINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 57. ASIA-PACIFIC CHINESE PATENT MEDICINE, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 58. ASIA-PACIFIC CHINESE PATENT MEDICINE, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 59. ASIA-PACIFIC CHINESE PATENT MEDICINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 60. ASIA-PACIFIC CHINESE PATENT MEDICINE, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 61. CHINA CHINESE PATENT MEDICINE, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 62. CHINA CHINESE PATENT MEDICINE, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 63. CHINA CHINESE PATENT MEDICINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 64. JAPAN CHINESE PATENT MEDICINE, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 65. JAPAN CHINESE PATENT MEDICINE, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 66. JAPAN CHINESE PATENT MEDICINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 67. INDIA CHINESE PATENT MEDICINE, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 68. INDIA CHINESE PATENT MEDICINE, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 69. INDIA CHINESE PATENT MEDICINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 70. SOUTH KOREA CHINESE PATENT MEDICINE, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 71. SOUTH KOREA CHINESE PATENT MEDICINE, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 72. SOUTH KOREA CHINESE PATENT MEDICINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 73. AUSTRALIA CHINESE PATENT MEDICINE, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 74. AUSTRALIA CHINESE PATENT MEDICINE, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 75. AUSTRALIA CHINESE PATENT MEDICINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 76. THAILAND CHINESE PATENT MEDICINE, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 77. THAILAND CHINESE PATENT MEDICINE, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 78. THAILAND CHINESE PATENT MEDICINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 79. MALAYSIA CHINESE PATENT MEDICINE, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 80. MALAYSIA CHINESE PATENT MEDICINE, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 81. MALAYSIA CHINESE PATENT MEDICINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 82. INDONESIA CHINESE PATENT MEDICINE, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 83. INDONESIA CHINESE PATENT MEDICINE, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 84. INDONESIA CHINESE PATENT MEDICINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 85. REST OF ASIA PACIFIC CHINESE PATENT MEDICINE, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 86. REST OF ASIA PACIFIC CHINESE PATENT MEDICINE, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 87. REST OF ASIA PACIFIC CHINESE PATENT MEDICINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 88. LAMEA CHINESE PATENT MEDICINE, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 89. LAMEA CHINESE PATENT MEDICINE, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 90. LAMEA CHINESE PATENT MEDICINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 91. LAMEA CHINESE PATENT MEDICINE, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 92. BRAZIL CHINESE PATENT MEDICINE, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 93. BRAZIL CHINESE PATENT MEDICINE, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 94. BRAZIL CHINESE PATENT MEDICINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 95. SOUTH AFRICA CHINESE PATENT MEDICINE, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 96. SOUTH AFRICA CHINESE PATENT MEDICINE, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 97. SOUTH AFRICA CHINESE PATENT MEDICINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 98. SAUDI ARABIA CHINESE PATENT MEDICINE, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 99. SAUDI ARABIA CHINESE PATENT MEDICINE, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 100. SAUDI ARABIA CHINESE PATENT MEDICINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 101. UAE CHINESE PATENT MEDICINE, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 102. UAE CHINESE PATENT MEDICINE, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 103. UAE CHINESE PATENT MEDICINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 104. ARGENTINA CHINESE PATENT MEDICINE, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 105. ARGENTINA CHINESE PATENT MEDICINE, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 106. ARGENTINA CHINESE PATENT MEDICINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 107. REST OF LAMEA CHINESE PATENT MEDICINE, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 108. REST OF LAMEA CHINESE PATENT MEDICINE, BY DOSAGE TYPE, 2022-2032 ($MILLION)
  • TABLE 109. REST OF LAMEA CHINESE PATENT MEDICINE, BY END USER, 2022-2032 ($MILLION)
  • TABLE 110. GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS COMPANY LIMITED: KEY EXECUTIVES
  • TABLE 111. GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS COMPANY LIMITED: COMPANY SNAPSHOT
  • TABLE 112. GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS COMPANY LIMITED: OPERATING SEGMENTS
  • TABLE 113. GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS COMPANY LIMITED: PRODUCT PORTFOLIO
  • TABLE 114. GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS COMPANY LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 115. YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD.: KEY EXECUTIVES
  • TABLE 116. YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD.: COMPANY SNAPSHOT
  • TABLE 117. YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD.: OPERATING SEGMENTS
  • TABLE 118. YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 119. YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 120. CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED: KEY EXECUTIVES
  • TABLE 121. CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED: COMPANY SNAPSHOT
  • TABLE 122. CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED: OPERATING SEGMENTS
  • TABLE 123. CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED: PRODUCT PORTFOLIO
  • TABLE 124. CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 125. SHANGHAI PHARMACEUTICAL CO., LTD.: KEY EXECUTIVES
  • TABLE 126. SHANGHAI PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
  • TABLE 127. SHANGHAI PHARMACEUTICAL CO., LTD.: OPERATING SEGMENTS
  • TABLE 128. SHANGHAI PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 129. SHANGHAI PHARMACEUTICAL CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 130. TAIJI GROUP CO., LTD.: KEY EXECUTIVES
  • TABLE 131. TAIJI GROUP CO., LTD.: COMPANY SNAPSHOT
  • TABLE 132. TAIJI GROUP CO., LTD.: OPERATING SEGMENTS
  • TABLE 133. TAIJI GROUP CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 134. TAIJI GROUP CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 135. TASLY.PHAR. INTERNATIONAL CO., LTD.: KEY EXECUTIVES
  • TABLE 136. TASLY.PHAR. INTERNATIONAL CO., LTD.: COMPANY SNAPSHOT
  • TABLE 137. TASLY.PHAR. INTERNATIONAL CO., LTD.: OPERATING SEGMENTS
  • TABLE 138. TASLY.PHAR. INTERNATIONAL CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 139. TASLY.PHAR. INTERNATIONAL CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 140. YUNNAN BAIYAO GROUP CO., LTD.: KEY EXECUTIVES
  • TABLE 141. YUNNAN BAIYAO GROUP CO., LTD.: COMPANY SNAPSHOT
  • TABLE 142. YUNNAN BAIYAO GROUP CO., LTD.: OPERATING SEGMENTS
  • TABLE 143. YUNNAN BAIYAO GROUP CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 144. YUNNAN BAIYAO GROUP CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 145. ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL CO., LTD.: KEY EXECUTIVES
  • TABLE 146. ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
  • TABLE 147. ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL CO., LTD.: OPERATING SEGMENTS
  • TABLE 148. ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 149. ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 150. SHANDONG DONG-E E-JIAO CO., LTD.: KEY EXECUTIVES
  • TABLE 151. SHANDONG DONG-E E-JIAO CO., LTD.: COMPANY SNAPSHOT
  • TABLE 152. SHANDONG DONG-E E-JIAO CO., LTD.: OPERATING SEGMENTS
  • TABLE 153. SHANDONG DONG-E E-JIAO CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 154. SHANDONG DONG-E E-JIAO CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 155. TIBET RHODIOLA PHARMACEUTICAL HOLDING CO., LTD.: KEY EXECUTIVES
  • TABLE 156. TIBET RHODIOLA PHARMACEUTICAL HOLDING CO., LTD.: COMPANY SNAPSHOT
  • TABLE 157. TIBET RHODIOLA PHARMACEUTICAL HOLDING CO., LTD.: OPERATING SEGMENTS
  • TABLE 158. TIBET RHODIOLA PHARMACEUTICAL HOLDING CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 159. TIBET RHODIOLA PHARMACEUTICAL HOLDING CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL CHINESE PATENT MEDICINE MARKET SEGMENTATION
  • FIGURE 2. GLOBAL CHINESE PATENT MEDICINE MARKET
  • FIGURE 3. SEGMENTATION CHINESE PATENT MEDICINE MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN CHINESE PATENT MEDICINE MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALCHINESE PATENT MEDICINE MARKET
  • FIGURE 11. CHINESE PATENT MEDICINE MARKET SEGMENTATION, BY DISEASE TYPE
  • FIGURE 12. CHINESE PATENT MEDICINE MARKET FOR CARDIOVASCULAR AND CEREBROVASCULAR DISEASES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. CHINESE PATENT MEDICINE MARKET FOR TUMOR DISEASES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. CHINESE PATENT MEDICINE MARKET FOR RESPIRATORY SYSTEM DISEASES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. CHINESE PATENT MEDICINE MARKET FOR MUSCULOSKELETAL DISEASES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. CHINESE PATENT MEDICINE MARKET FOR DIGESTIVE SYSTEM DISEASES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. CHINESE PATENT MEDICINE MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. CHINESE PATENT MEDICINE MARKET SEGMENTATION, BY DOSAGE TYPE
  • FIGURE 19. CHINESE PATENT MEDICINE MARKET FOR INJECTION, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. CHINESE PATENT MEDICINE MARKET FOR CAPSULE, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. CHINESE PATENT MEDICINE MARKET FOR PILLS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. CHINESE PATENT MEDICINE MARKET FOR SYRUPS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. CHINESE PATENT MEDICINE MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 24. CHINESE PATENT MEDICINE MARKET SEGMENTATION, BY END USER
  • FIGURE 25. CHINESE PATENT MEDICINE MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 26. CHINESE PATENT MEDICINE MARKET FOR PHARMACIES OR DRUGSTORES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 27. CHINESE PATENT MEDICINE MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 28. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 29. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 30. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 31. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 32. COMPETITIVE DASHBOARD
  • FIGURE 33. COMPETITIVE HEATMAP: CHINESE PATENT MEDICINE MARKET
  • FIGURE 34. TOP PLAYER POSITIONING,2022
  • FIGURE 35. GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS COMPANY LIMITED: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 36. GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS COMPANY LIMITED: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 37. GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS COMPANY LIMITED: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 38. YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 39. YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 40. YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 41. CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 42. CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 43. CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 44. SHANGHAI PHARMACEUTICAL CO., LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 45. SHANGHAI PHARMACEUTICAL CO., LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 46. SHANGHAI PHARMACEUTICAL CO., LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 47. TAIJI GROUP CO., LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 48. TAIJI GROUP CO., LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 49. TAIJI GROUP CO., LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 50. TASLY.PHAR. INTERNATIONAL CO., LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 51. TASLY.PHAR. INTERNATIONAL CO., LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 52. TASLY.PHAR. INTERNATIONAL CO., LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 53. YUNNAN BAIYAO GROUP CO., LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 54. YUNNAN BAIYAO GROUP CO., LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 55. YUNNAN BAIYAO GROUP CO., LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 56. ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL CO., LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 57. ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL CO., LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 58. ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL CO., LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 59. SHANDONG DONG-E E-JIAO CO., LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 60. SHANDONG DONG-E E-JIAO CO., LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 61. SHANDONG DONG-E E-JIAO CO., LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 62. TIBET RHODIOLA PHARMACEUTICAL HOLDING CO., LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 63. TIBET RHODIOLA PHARMACEUTICAL HOLDING CO., LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 64. TIBET RHODIOLA PHARMACEUTICAL HOLDING CO., LTD.: REVENUE SHARE, BY REGION, 2032 (%)

Purchase Full Report of
Chinese Patent Medicine Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved